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Background
With 10–15 million of people infected with Trypanosoma cruzi
(Kinetoplastida: Trypanosomatidae) and many more exposed to
risk of infection, the burden of Chagas disease in Latin America
amounts to as much as 2.7 times the combined burden of malaria,
schistosomiasis, leishmaniasis, and leprosy in 2002 [1]. Following a
short, mostly subclinical acute phase and a very long asymptom-
atic phase with very low parasitemia, 25%–40% of infected
humans develop chronic disease with cardiac, digestive, or
neurologic manifestations that leads to a reduced life span [2].
Human transmission of T. cruzi is mediated by nearly a dozen
blood-sucking species of triatomine bugs that infest resource-
limited, rural houses and their outbuildings, but it may also occur
by blood transfusions and from infected mothers to their children.
A series of intergovernmental control initiatives led by the Pan
American Health Organization were launched in Latin America
during the 1990s with the objectives of eliminating transmission of
T. cruzi by blood transfusion and by domestic populations of
triatomine bugs by the year 2010 [2,3]. Control actions reduced the
geographic range and infestation prevalence of major triatomine
vectorsandledtotheinterruptionoftransmissioninUruguay,Chile,
and Brazil, and to significant improvements in Central America and
elsewhere [2,3]. However, active vector-borne transmission persists
in vast areas of Argentina [3,4], El Salvador, and Colombia, among
others; and several countries (Mexico, Peru, Colombia, and Costa
Rica) have no national programs for the control of Chagas disease
vectors [5]. The growing decentralization of vector control
operations to the provincial and municipal levels since the early
1980s added the still-unmet challenge of coordinating efforts among
districts differing in infestation, control status, resources, and
priorities, and between national, provincial, and municipal public
health levels [6].
Large-scale screening of blood donors in Latin America began
in the 1980s following the emergence of AIDS, and currently is in
place in nearly all countries, though at differing coverage rates.
These programs brought about a significant reduction in the
prevalence of T. cruzi infection among blood donors in most of the
region [7]. Although most advances in the safety of the blood
supply since 1993 originated from increased screening coverage
for infectious diseases and better quality assurance, it has been
estimated that tainted blood may have caused T. cruzi infections in
12 of 17 Latin American countries over the period 2001 to 2002
[7]. With the sustained wave of immigration from Latin America
to US, Canada, and Western Europe, transplant- and transfusion-
related cases of Chagas disease jointly with congenital cases have
been reported more frequently in the target destinations.
Chagas disease control programs traditionally have focused on
interrupting vector- and blood-borne transmission of T. cruzi
rather than on active case detection and specific treatment of
infected people. One reason for this is that the only available drugs
for specific treatment of T. cruzi infection, nifurtimox (since 1967)
and benznidazole (since 1972), were traditionally considered
effective only during the acute phase of infection or shortly after
it. This notion persisted until two randomized clinical trials,
conducted with support from the World Health Organization’s
Special Programme for Research and Training in Tropical
Diseases (TDR) and national agencies during the 1990s,
demonstrated that most infections treated with benznidazole
during the early chronic phase (i.e., in seropositive children aged
#12 y with unknown duration of infection) could be cured [8–11].
In the meantime, experimental studies changed the view that
Chagas disease is primarily an autoimmune response toward one
that the disease is a problem of parasite persistence [12]. In
addition, the progress in vector control status achieved during the
last decades has paved the way to conceiving the specific treatment
of T. cruzi-infected children residing in traditionally endemic rural
settings (e.g., Argentina, Bolivia). More recently, specific treatment
has been extended to seropositive children aged #15 y in some
countries, and is being offered more frequently to adults with long-
term chronic infections because it might moderate disease
progression [13]. Because individuals in the chronic stage display
a long-lasting serological response to T. cruzi infection after specific
treatment, in some cases demonstration of cure by means of
conventional serological methods may take more than 10 y [9].
The efficacy of anti-trypanosomal drugs apparently decreases with
the duration of infection, whereas their adverse effects increase
with age and occasionally may be serious if treatment is not
discontinued and proper care given [14,15]. As the new study by
Levy et al. [16] published in PLoS Neglected Tropical Diseases stresses,
‘‘…without timely diagnosis, children infected [with T. cruzi] prior
to implementation of vector control often miss the window of
opportunity for effective chemotherapy.’’
Another important reason for the observed low rates of specific
treatment of children seropositive for T. cruzi is that health services
and Chagas disease control programs in Latin America lack or do
not allocate sufficient resources for comprehensive serological
screening and supervised treatment in the most affected endemic
areas. There, health services usually are understaffed and
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combat domestic reinfestation after massive insecticide spraying
campaigns [4]. The usual approaches to active case detection
require surveying the whole population at risk (in house-to-house
or school-based surveys), and therefore are labor-intensive and
costly. It is in this context that the article by Levy et al. [16] attains
high relevance for the pending task of massive case detection and
treatment of infected children in resource-poor settings.
A new study on targeted control strategies for
Chagas disease
Michael Levy et al. [16,17] describe for the first time the
emergence of T. cruzi transmission in an urban or periurban
environment, and its possible epidemic spread from one or several
points of parasite introduction in a geographically defined area in
the city of Arequipa, Peru. The primary aim of the study was to
develop targeted screening strategies to detect T. cruzi infection in
children from data collected during a vector control campaign
directed against the major vector Triatoma infestans. Although
household clustering of T. cruzi infection and vector infestation has
long been known [18–20], the researchers are also the first to
describe the spatial aggregation of seropositive children within
looser clusters of infected vectors.
The researchers took a simple and direct approach to detecting
infected children. They accompanied vector control program
operations in one community to collect entomological, demo-
graphic, and environmental data as residual insecticide spraying
was carried out at each geo-referenced household; they then
performed a cross-sectional serological survey for T. cruzi infection
among children aged #18 y and mapped out the occurrence and
densities of vectors, infected vectors, and seropositive children. By
using spatial analysis and multivariate Bayesian modelling
techniques, the researchers identified clusters with children at
high risk of infection for targeted screening and treatment, and
evaluated the benefits of alternative screening strategies.
Among the main study findings, child infections were
geographically clustered and apparently occurred at all vector
density levels. Significant spatial clustering of seropositivity among
children occurred up to 270 m of an identified case. A key result
from the modeling effort is that 83% of infected children could be
identified while testing only 22% of eligible children. The
researchers then devised a two-step screening strategy that, for
the first step, begins by ranking children based on their age and the
relative density of vectors captured within their houses (prelimi-
nary screening), and then examines for infection a proportion of
the children predicted to be at highest risk. In the second step of
screening, the information on the detected seropositive children is
used to identify and test other children living within given
distances from the former (ring screening). As in earlier studies
[18,19,21], child seropositivity was significantly associated with
domestic vector densities and child age; additional information on
whether domestic T. infestans were infected with T. cruzi (involving
laborious procedures) did not improve the ability of the model to
predict child infection. The article also reminds us of the
outstanding ability of the vector to infest urban environments
with substandard housing and transmit T. cruzi to humans.
Strengths and limitations of the study
Major strengths of the Levy and colleagues study may be found
at levels that encompass study design and careful data collection in
a well-defined area, to data analysis with sophisticated statistical
methods and cautious interpretation of findings.
Lack of demographic and behavioral data limit the interpreta-
tion of results to some extent. Additional information on the
individual timing of settlement (including birthplace, residence
period, and travel history) and the main geographic sources of
immigration would contribute to a better understanding of the
transmission system and could help corroborate whether all child
infections were vector-borne and autochthonous, as the spatial
analysis and the identified vector-related predictors suggest.
Although most of the study children were born in Arequipa,
those in the older age group (close to 18 y old) and elder family
members likely became infected elsewhere, given that they were
rural immigrants relocated to periurban settlements from 1980 to
1995 to escape from terrorism [17]. This detail does not conspire
against the primary aim of the study (i.e., identifying the infected
children regardless of the origin of the infection), but it affects
more refined elaborations of the relationship between risk of
infection, vector densities, and transmission thresholds. Measure-
ment of transmission thresholds is fraught with several sources of
inaccuracy [21], and in the best case they might only be achieved
through a prospective study.
As the authors acknowledge, individual information on migration,
the participants’ maternal seropositivity status, history of previous
blood transfusions, and householders’ vector control practices would
be most valuable, and may explain some of the cases missed by the
models. For research purposes and refinement of the models,
collecting data on potential predictors that may increase the models’
ability to identify the locations of infected children may help reduce
the fraction of infections lost to detection and subsequent treatment.
This is a crucial point related to equity, because in the absence of
subsequent screening instances the infected children lost to detection
would also lose the (currently suggested) window of opportunity for
effective specific treatment of T. cruzi infections. Such a window of
opportunity is itself a matter of controversy [11,13,15,22]. The
utilization of highly sensitive rapid (dipstick) tests for detecting
antibodies to T. cruzi in finger-prick blood samples may simplify and
speed up the screening stage at a moderate net cost relative to
standard laboratory-based diagnosis of serum samples drawn by
venipuncture [23]. Increasing the sensitivity of the screening models
at the expense of its specificity is clearly indicated as the next step.
Replication of the targeted approach to detection and treatment in
communities that have recently experienced higher levels of
transmission, and therefore have a larger number of infected
children to identify and treat, would be very useful.
Implications of the study for Chagas disease
control
Levy et al. [16] raise two subjects that are rarely debated in the
field of Chagas disease control: the optimal use of limited
resources, and the integration of case detection and treatment of
children into disease control programs that traditionally have
focused on vector control. Mathematical modelling also supports
the hypothesis that vector control combined with specific
treatment is highly cost-effective compared with vector control
alone [24]. Lack of integration between both components entails
lost opportunities for improved disease control.
A major contribution of this article is the identification of ‘‘hot
spots’’ of infestation and transmission within an apparently
homogeneous community. The identification of such ‘‘hot spots’’
would not only enable more targeted case detection and prompt
treatment, as the authors emphasize, but it may also contribute to
improved prevention of transmission after residual insecticide
spraying [25]. T. cruzi infection in domestic dogs and cats was
highly aggregated at the household level and fell close to the 80/20
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households makes a disproportionate contribution ($80%) to
infection prevalence [27]. Moreover, the infectiousness of domestic
dogs seropositive for T. cruzi to triatomine bugs was also highly
aggregated at the population level [28]. Targeted case detection
and treatment combined with selective vector control would not
only increase the impact and cost effectiveness of the control
program, but it could also help increase its public acceptance and
long-term sustainability, as observed in a long-term prospective
study in northern Argentina [4].
It is beyond dispute that benznidazole and nifurtimox should be
more widely used for specific treatment of T. cruzi infection in
children at all stages of the disease. Although the supply of these
drugs has recently improved [5], access to them in some endemic
settings remains problematic. In traditionally endemic settings
where reinfestation is recurrent, vector surveillance and control
systems need to be established or strengthened before specific
treatments are made available more widely. Beyond targeted
detection, sustainable vector surveillance, and better access to
drugs, we still need to increase awareness of treatment opportu-
nities in the medical sector serving endemic settings and in the
affected population groups, and to train local physicians in the
supervised treatment of children seropositive for T. cruzi.
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